Oral contraceptive use influences resting breast proliferation

Human Pathology

Volumn 20, Issue 12, 1989, Pages 1139-1144

  Anderson, Thomas J ^a,b,c   Battersby, Sharon ^a,b,c   King, Roger J B ^a,b,c   McPherson, Klim ^a,b,c   Going, James J ^a,b,c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

breast; epithelial proliferation; menstrual cycle; oral contraceptive; parity

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RADIOISOTOPE;

ARTICLE; BREAST; CELL GROWTH; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0024836171     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(89)80003-6     Document Type: Article

References (38)

1. Breast cancer epidemiology
2. Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labelling with tritiated thymidine
3. Morphological evaluation of cell turnover in relation to the menstrual cycle in the “resting” human breast
4. Cell turnover in the “resting” human breast: Influence of parity, contraceptive pill, age and laterality
5. Cell proliferation in fibrocystic disease and postmenopausal breast ducts measured by thymidine labeling
6. Proliferative and seretory activity in human breast during natural and artificial menstrual cycles
7. The effect of age and menstrual cycle upon proliferative activity in the normal human breast
8. The effect of oestrogen, progesterone, thyroxine and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice
9. Maintenance of normal human breast organoids within rat mammary fat pads in organ culture
10. Oral contraceptives and breast cancer
11. The relation between oral contraceptive use and subsequent development of hyperprolactinemia
12. Hyperprolactinemia and contraception: A prospective study
13. Neuroendocrine dysfunction with psychogenic implications in post pill galactorrheaamenorrhea
14. Elevated levels of prolactin in nulliparous women
15. Long-term effect of a first pregnancy on the secretion of prolactin
16. Lack of toxicity of methylene blue chloride to supravitally stained human mammary tissues
17. Effects of oestrogens and progestin on the biochemistry and morphology of the postmenopausal endometrium
18. Assessment of the potency of orally administered progestins in women
19. Orally active progestational compounds. Human studies: Effects on the utero-vaginal tract
20. Influence of age and gland topography on cell kinetics of normal human breast
21. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast
22. Proliferative and secretory activity in the pregnant and lactating breast
23. Influence of pregnancy and lactation on serum and breast fluid oestrogen levels: Implications for breast cancer risk
24. Do hormones cause breast cancer?
25. Comment on progesterone effects in breast tissue
26. Breast cancer, pregnancy and the pill
27. Effects of progestin-oestrogen combination and progestational contraceptives on pituitary gonadotropins, gonadal steroids and sex hormone-binding globulin
28. Two oral contraceptives. Efficiency, serum proteins and lipid metabolism
29. Metabolic effects of the triphasic oral contraceptive Trigynon
30. Paracrine regulation of mammary gland growth
31. Human breast carcinoma cells produce growth regulatory peptides
32. Chronic mastopathy and breast cancer
33. Risk of breast cancer in women with benign breast disease
34. Risk factors for breast cancer in women with proliferative breast disease
35. A prospective study of the development of breast cancer in 16,692 women with benign breast disease
36. Breast cancer in young women and use of oral contraceptives. Modifying effect of formulation and age at use
37. Early oral contraceptive use and breast cancer: Results of another case control study